Anti-Diabetes Drugs - China | Statista Market Forecast

In 2024, the projected revenue in the Anti-Diabetes Drugs market in China is estimated to reach US$9.46bn.
Furthermore, it is expected that this revenue will experience an annual growth rate (CAGR 2024-2029) of 7.85%.
As a result, the market volume is projected to reach US$13.81bn by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue in the market, amounting to US$37.84bn in 2024.
China is experiencing a surge in demand for innovative anti-diabetes drugs due to its growing diabetic population and increased healthcare spending.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

Anti-Diabetes Drugs market has been one of the fastest-growing pharmaceutical markets in China.

Customer preferences: The increasing prevalence of diabetes in China has led to a significant rise in demand for anti-diabetes drugs. The Chinese population is aging rapidly, and unhealthy lifestyles have contributed to the high incidence of diabetes in the country. Additionally, the growing awareness of diabetes and its complications has led to an increased demand for anti-diabetes drugs.

Trends in the market: The anti-diabetes drugs market in China is primarily driven by the increasing prevalence of diabetes in the country. The market is dominated by big multinational pharmaceutical companies, which account for a significant share of the market. The market for anti-diabetes drugs in China is expected to grow at a steady pace in the coming years, driven by the increasing incidence of diabetes and the growing demand for effective and affordable drugs.

Local special circumstances: China has a unique healthcare system, which is heavily influenced by the government. The government plays a significant role in regulating the pharmaceutical industry, including the pricing of drugs. The government's focus on providing affordable healthcare to its citizens has led to the implementation of price controls on drugs, which has impacted the profitability of pharmaceutical companies operating in the country.

Underlying macroeconomic factors: The Chinese economy has been growing at a steady pace, which has led to an increase in the disposable income of the population. This has contributed to the growing demand for healthcare services, including anti-diabetes drugs. The Chinese government has also been investing heavily in the healthcare sector, which has led to the expansion of healthcare facilities and the improvement of the healthcare infrastructure in the country. These factors are expected to drive the growth of the anti-diabetes drugs market in China in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.